Hepatitis C: new treatment overview.
Stoia
J
J
D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004349:Drug Packaging; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D020407:Internet; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin